Axsome Therapeutics (AXSM) Getting Favorable News Coverage, Report Finds

News headlines about Axsome Therapeutics (NASDAQ:AXSM) have been trending positive on Friday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Axsome Therapeutics earned a news impact score of 0.27 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.4684472420632 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Several brokerages have commented on AXSM. Zacks Investment Research lowered Axsome Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th. ValuEngine raised Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $16.90.

How to Become a New Pot Stock Millionaire

Shares of AXSM opened at $2.35 on Friday. Axsome Therapeutics has a one year low of $2.05 and a one year high of $6.45. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.90 and a quick ratio of 2.90.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Wednesday, March 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. research analysts predict that Axsome Therapeutics will post -0.26 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Axsome Therapeutics (AXSM) Getting Favorable News Coverage, Report Finds” was posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/06/axsome-therapeutics-axsm-receiving-favorable-press-coverage-report-shows/2030406.html.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The company's product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and Alzheimer's disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes.

Insider Buying and Selling by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.